Are you Dr. Juergens?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1650 Orleans St
Johns Hopkins Crb I -G93
Baltimore, MD 21287Phone+1 410-955-8893
Summary
- Dr. Rosalyn Juergens, MD is an oncologist in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland.
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006- Johns Hopkins UniversityResidency, Internal Medicine, 2000 - 2003
Georgetown University School of MedicineClass of 2000
Certifications & Licensure
MD State Medical License 2003 - 2022- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery Start of enrollment: 2010 Sep 01
- An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026) Start of enrollment: 2014 Mar 27
Publications & Presentations
PubMed
- 6 citationsCurrent and Future Treatment Options in the Management of Stage III NSCLC.Yuchen Li, Rosalyn Anne Juergens, Christian Finley, Anand Swaminath
Journal of Thoracic Oncology. 2023-11-01 - 3 citationsThe dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.Barbara Melosky, Parneet Cheema, Rosalyn A. Juergens, Natasha B. Leighl, Geoffrey Liu
Therapeutic Advances in Medical Oncology. 2021-11-15 - 4 citationsCanadian Consensus Recommendations on the Management of MET-Altered NSCLCParneet K. Cheema, Shantanu Banerji, Normand Blais, Quincy Chu, Patrice Desmeules
Current Oncology. 2021-11-09
Press Mentions
Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca™ (Lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a DecadeNovember 30th, 2021
Health Canada Approves Tecentriq(atezolizumab), First New Treatment in 20 Years for Aggressive Form of Lung Cancer(1)August 13th, 2019
Lung Cancer ‘Not One Big Disease’March 20th, 2018- Join now to see all
